Ibrutinib frontline in young patients with CLL
- PMID: 35834283
- DOI: 10.1182/blood.2022016535
Ibrutinib frontline in young patients with CLL
Comment on
-
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960. Blood. 2022. PMID: 35427411 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources